Our global life sciences company brings diagnostic testing & drug development together. Explore what we do.
Monogram has expanded its expertise in virology and base phenotyping technology to address the need for high-throughput, quantitative resistance testing assays for various respiratory and other viral illnesses. Monogram has also developed and validated a number of additional assays to offer broad preclinical and clinical trial support.
Download a slide deck outlining our capabilities with respiratory and other viruses.
Monogram is applying its experience in providing valuable, high-throughput neutralizing antibody data for HIV vaccine development to influenza and other clinically important viruses. Using the same base technology as our phenotyping assays, Monogram is able to measure the breadth, potency, and potential efficacy of specific antibodies against well-characterized heterologous and autologous strains of the influenza virus. Data is reported in the form of phenotypic susceptibility curves, IC50, 80 90 and 95 tables, or as a percentage inhibition at each tested antibody dilution.
Monogram is in the process of developing a quantitative cell-based infectivity assay to measure respiratory syncytial virus (RSV) resistance to entry/fusion inhibitors and neutralizing antibodies. Additionally, using next-generation sequencing, Monogram can sequence and analyze P (polymerase) and F (fusion), G, and SH env genes
Monogram has developed and characterized a high-throughput, quantitative, cell-based neutralizing antibody assay for Ebola to assist vaccine designers in evaluating the humoral response in preclinical and clinical trials of candidate vaccines.
Monogram also offers the GenMark Respiratory Virus Panel, an assay that identifies up to 19 pathogenic respiratory viruses in clinical samples and can be instrumental in enrolling patients for influenza and other respiratory clinical trials.
In addition to lentiviruses (HIV-1, HIV-2, simian-human immunodeficiency virus [SHIV], simian immunodeficiency virus [SIV]) and myxoviruses (influenza A, B,) our platform technology can be applied broadly to the measurement of neutralizing antibody responses to a wide variety of enveloped viruses that include: